Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes-Reference-Cited by-同舟云学术

Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes

Published:2020-11-06 Issue:45 Volume:99 Page:e23060
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Emsen Berivan,Villafane Gabriel,David Jean-Philippe,Evangelista Eva,Chalaye Julia,Lerman Lionel,Authier François-Jérôme,Gracies Jean-Michel,Itti Emmanuel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference23 articles.

1. Science, medicine, and the future: Parkinson's disease;Schapira;Br Med J,1999

2. Cerebral metabolism of 6–[18F]Fluoro-l-3,4-dihydroxyphenylalanine in the primate;Firnau;J Neurochem,1987

3. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls;Eshuis;Eur J Nucl Med Mol Imaging,2009

4. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices;Pate;Ann Neurol,1993

5. Positron emission tomography imaging of regional cerebral glucose metabolism;Alavi;Semin Nucl Med,1986

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine Synthesis in the Nigrostriatal Dopaminergic System in Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage;Journal of Clinical Medicine;2024-02-02

2. Brain PET Imaging;PET Clinics;2023-01

3. Molecular Imaging in Neurology;Molecular Imaging and Targeted Therapy;2023

4. Molecular Imaging and Targeted Radionuclide Therapy: Introduction;Molecular Imaging and Targeted Therapy;2023

5. Requirements of Scintillation Crystals with the Development of PET Scanners;Crystals;2022-09-15